Law.com Subscribers SAVE 30%

Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.

Movers & Shakers Image

Movers & Shakers

ALM Staff & Law Journal Newsletters

Who's going where; who's doing what.

Verdicts Image

Verdicts

ALM Staff & Law Journal Newsletters

Recent rulings of importance to you and your practice.

Drug & Device News Image

Drug & Device News

ALM Staff & Law Journal Newsletters

The most recent news for your review.

Features

Med Mal News Image

Med Mal News

ALM Staff & Law Journal Newsletters

Recent events you need to know.

Features

Trial Tactics in Psychiatrist Liability Cases Image

Trial Tactics in Psychiatrist Liability Cases

Joshua D. Koskoff

The average juror may not be aware of the extent of mental-health professionals' duty to protect innocent third parties from their dangerous patients, and they may be reluctant to hold these professionals responsible. Following are some strategies that will help to get the plaintiff's point of view across to the fact finder.

Experimental Drugs and the Compassionate Use Doctrine Image

Experimental Drugs and the Compassionate Use Doctrine

Janice G. Inman

While gaining access to drugs not yet approved by the FDA can be a difficult task, many people will go to nearly any lengths to get them, even suing a drug manufacturer to force it to provide them the drug. That's what happened in the case of <i>Gunvalson v. PTC Therapeutics Inc.</i>, a case recently overturned on appeal.

Features

Spoliation in a Medical Malpractice Case Image

Spoliation in a Medical Malpractice Case

Kim M. Ruder

Spoliation in the context of a medical malpractice case can raise many issues for lawyers representing doctors and hospitals. These issues can often be overlooked until it is too late to repair the damage done.

Features

<b>BREAKING NEWS:</b> Eli Lilly to Pay $1.42 Billion to Settle Zyprexa Marketing Suits Image

<b>BREAKING NEWS:</b> Eli Lilly to Pay $1.42 Billion to Settle Zyprexa Marketing Suits

Shannon P. Duffy

Eli Lilly &amp; Co. will pay a combined $1.42 billion, including the largest criminal fine in history ' $515 million ' to settle charges that it illegally marketed the anti-psychotic drug Zyprexa for off-label use, federal prosecutors announced on Jan. 15.

Movers & Shakers Image

Movers & Shakers

ALM Staff & Law Journal Newsletters

Who's doing what; who's going where.

Verdicts Image

Verdicts

ALM Staff & Law Journal Newsletters

Recent rulngs of importance to you and your practice.

Need Help?

  1. Prefer an IP authenticated environment? Request a transition or call 800-756-8993.
  2. Need other assistance? email Customer Service or call 1-877-256-2472.

MOST POPULAR STORIES

  • The Roadmap of Litigation Analytics
    Litigation analytics can be considered a roadmap of sorts — an important guide to ensure the legal professional arrives at the correct litigation strategy or business plan. However, like roadmaps, litigation analytics will only be useful if it's based on data that is complete and accurate.
    Read More ›
  • Understanding the Potential Pitfalls Arising From Participation in Standards Bodies
    Chances are that if your company is involved in research and development of new technology there is a standards setting organization exploring the potential standardization of such technology. While there are clear benefits to participation in standards organizations &mdash; keeping abreast of industry developments, targeting product development toward standard compliant products, steering research and intellectual property protection into potential areas of future standardization &mdash; such participation does not come without certain risks. Whether you are in-house counsel or outside counsel, you may be called upon to advise participants in standard-setting bodies about intellectual property issues or to participate yourself. You may also be asked to review patent policy of the standard-setting body that sets forth the disclosure and notification requirements with respect to patents for that organization. Here are some potential patent pitfalls that can catch the unwary off-guard.
    Read More ›